Discovery and validation of islet regenerative proteins secreted by human multipotent stromal cells
Open Access
- 27 April 2026
- journal article
- Published by Oxford University Press (OUP) in Stem Cells Translational Medicine
- Vol. 15 (5)
Abstract
Introduction: Diabetes affects >500 million people worldwide. Despite insulin therapy, most patients develop devastating complications, emphasizing the need for curative strategies. Human multipotent stromal/stem cells (MSC) secrete factors that promote islet regeneration. We previously showed that intrapancreatic (iPan) delivery of Wnt-activated MSC-conditioned media (Wnt+ CM) stimulates islet regeneration without cell transfer. This study aimed to identify and functionally validate specific MSC-secreted proteins with islet regenerative potential. Methods: Comprehensive mass spectrometry-based, quantitative proteomic analyses comparing Wnt-pathway activated versus untreated MSC secretomes were cross-referenced with a prior dataset distinguishing regenerative from nonregenerative MSC CM. Proteins enriched in both conditions were iPan-injected individually or in combination into streptozotocin-treated NOD/SCID mice. Nonfasting glucose, glucose tolerance, beta cell mass, islet morphology, and islet cell proliferation were assessed at 4- and 32-days post-treatment. Results: Cross-referenced secretome analyses identified eight proteins implicated in islet regeneration: CALU, CTSB, FAM3C, GAL1, PPIA, PSAP, SOD1, and TGM2. A single iPan-injection of the 8-protein combination significantly lowered hyperglycemia, improved glucose tolerance, and increased beta cell mass, comparable to Wnt+ CM. Regenerative effects such as increased beta cell proliferation appeared as early as day 4. Single-protein testing identified CALU and SOD1 as leading candidates, improving glucose tolerance and reducing nonfasting glucose. Conclusion: This study defines a set of MSC-secreted proteins that promote islet regeneration in vivo, supporting the development of protein-based biologics to preserve or restore beta cell function during diabetes, with potential applications alongside islet replacement therapies to enhance graft survival and function.Keywords
Funding Information
- Canadian Institutes of Health Research (378189)
- Sheldon H. Weinstein Chair in Diabetes Research at the Schulich School of Medicine and Dentistry
- Western University
This publication has 57 references indexed in Scilit:
- Insulin: Potential Negative Consequences of Early Routine Use in Patients With Type 2 DiabetesDiabetes Care, 2011
- Transplanted Human Bone Marrow Progenitor Subtypes Stimulate Endogenous Islet Regeneration and RevascularizationStem Cells and Development, 2011
- A Perivascular Origin for Mesenchymal Stem Cells in Multiple Human OrgansCell Stem Cell, 2008
- International Trial of the Edmonton Protocol for Islet TransplantationNew England Journal of Medicine, 2006
- Exendin-4 treatment improves metabolic control after rat islet transplantation to athymic mice with streptozotocin-induced diabetesDiabetologia, 2006
- The Vascular Basement Membrane: A Niche for Insulin Gene Expression and β Cell ProliferationDevelopmental Cell, 2006
- Five-Year Follow-Up After Clinical Islet TransplantationDiabetes, 2005
- Adult pancreatic β-cells are formed by self-duplication rather than stem-cell differentiationNature, 2004
- Bone marrow–derived stem cells initiate pancreatic regenerationNature Biotechnology, 2003
- Islet Transplantation in Seven Patients with Type 1 Diabetes Mellitus Using a Glucocorticoid-Free Immunosuppressive RegimenNew England Journal of Medicine, 2000